JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE) ›› 2021, Vol. 41 ›› Issue (4): 530-534.doi: 10.3969/j.issn.1674-8115.2021.04.019

• Review • Previous Articles     Next Articles

Review and prospect of anti-vascular endothelial growth factor treatment for wet age-related macular degeneration

Ya-fang WANG(), Yang LIU, Xue-ting LUO()   

  1. Department of Ophthalmology, Shanghai General Hospital, Shanghai Jiao Tong University; National Clinical Research Center for Eye Diseases; Shanghai Key Laboratory of Ocular Fundus Diseases; Shanghai Engineering Center for Visual Science and Photomedicine; Shanghai Engineering Center for Precise Diagnosis and Treatment of Eye Diseases, Shanghai 200080, China
  • Received:2020-01-11 Online:2021-04-28 Published:2021-05-14
  • Contact: Xue-ting LUO;
  • Supported by:
    National Natural Science Foundation of China(81700828);National Key R&D Program of China(2016YFC0904800);National Science and Technology Major Project of China(2017ZX09304010)


Anti-vascular endothelial growth factor (VEGF) has been the first choice in the treatment of wet age-related macular degeneration (AMD), since ranibizumab went on sale in 2006. However, clinical studies have suggested that the visual acuity returned to a baseline level several years after anti-VEGF therapy, with the occurrence of retinal fibrosis and geomorphologic atrophy, highlighting the limit of this treatment. In order to improve the efficacy, replacement and supplementation of traditional anti-VEGF emerged successively. Gene therapy achieved long-term and stable anti-VEGF effect by mediating therapeutic proteins delivered by adeno-associated virus vectors. Treatment combined with anti-platelet-derived growth factor may compensate for the limitations of anti-VEGF therapy through peripheral cells. Complement-related gene therapy is a new field based on the poor reactivity of patients against VEGF. This article reviews the progress of anti-VEGF in the treatment of wet AMD.

Key words: age-related macular degeneration, choroidal neovascularization, vascular endothelial growth factor

CLC Number: